MedTrace Logo

Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis

NCT03363685 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-10-08

No results posted yet for this study

Summary

The purpose of this study is to learn whether our own made predictive algorithm can be used as a clinical practical decision support for patients with NSCLC spinal metastasis. The scoring system consists of the use of EGFR-TKI, KPS, Age, SCC, CA125 and smoking history. By predicting survival doctors could determine which patients are suitable for palliative therapy.

Conditions

  • Spinal Metastases
  • Non-Small-Cell Lung Cancer Metastatic

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03363685 on ClinicalTrials.gov